oncology APISintaho Pharmaceutical Ltd was established in the year of 2016 and headquartered in Chongqing China, with a grand vison of being the most trusted partner to pharmaceutical companies worldwide. We have a clear focus on developing and manufacturing highly potent and cytotoxic Active Pharmaceutical Ingredients (APIs) and CDMO services.
*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Eribulin mesylate is a synthetic analog of halichondrin B, functioning as a microtubule dynamics inhibitor. <strong>Molecular Formula</strong>: C<sub>29</sub>H<sub>41</sub>NO<sub>6</sub>S; <strong>CAS No.</strong>: 170854-52-7. Produced via complex total synthesis with strict chiral control.</p>
<h3>Application</h3>
<ul>
<li><strong>Oncology Manufacturing</strong>: API production for metastatic breast cancer and unresectable liposarcoma therapies.</li>
<li><strong>Contract Research</strong>: Supply for preclinical pharmacological studies on tubulin polymerization inhibition.</li>
<li><strong>Distribution</strong>: Bulk supply to pharmaceutical formulators for oncology injectable formulations.</li>
</ul>
<h3>Precautions</h3>
<p>Strictly contraindicated in pregnancy due to teratogenicity. Requires storage at controlled room temperature (20°C–25°C) in light-resistant containers. Personnel must utilize PPE to prevent dermal exposure during handling.</p>